CD33 and acute myeloid leukemia: Unfortunately, frequently targeted antigens in AML CAR-T therapy, such as CD33 and CD123, found in around 80–90% and 70–80% of AML patients, respectively, are also detected on HSCs and normal myeloid progenitor cells (114).